Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib + Etoposide followed by Auto-HSCT for R/R ALK+ ALCL
NCT03707847Phase 4Unknown
- Start
- Oct 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of crizotinib in anaplastic large cell lymphoma (ALCL). Primary endpoints: Objective Response Rate up to 24 months and Progression-Free Survival up to 24 months. Status: unknown.
02
Drugs
crizotinib
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT03707847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707847.